Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

BCG dosing for bladder cancer: Standard frequency schedule correct

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 19.02.20
Views: 185

Prof Oliver Grimm - Universitätsklinikum Jena, Jena, Germany

Prof Oliver Grimm speaks to ecancer at the 2020 ASCO GU meeting at San Francisco about the results of the phase III NIMBUS trial looking at BCG dosing for bladder cancer.

He explains that the aim was to show that a reduced dosing schedule would be non-inferior to the standard schedule, however the experimental arm was found to be inferior to the standard frequency arm.

Prof Grimm states that we should therefore continue using the standard frequency as recommended but that they did make some interesting findings concerning recurrence in the standard frequency arm which can be attributed to the routine use of repeated TUR prior to BCG induction.

Related videos

follow us

WIN 2020

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation